In total, 169 patients participated in the survey; the majority of the patients stated their general health status as good (72.2%) and excellent (13.6%). Patients who rated their overall health status ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

In a real-world study, only 35% of patients completed the full guideline-recommended 4-6 cycles of chemotherapy as first-line treatment for metastatic bladder cancer. Real-world data show suboptimal ...

Pharmaceutical treatment for urinary tract infections (UTI) is significantly associated with a higher risk for a delayed diagnosis of muscle-invasive or metastatic bladder cancer. Treatment for ...

Urothelial carcinoma is cancer of the urinary system. The urothelium is a kind of epithelial (protective) lining of the urinary system, which includes the urinary tract, bladder, your ureters (the ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s cisplatin eligibility.